bs_bs_banner
Therapeutic Apheresis and Dialysis 2015; 19(3):199–200 doi: 10.1111/1744-9987.12321 © 2015 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society of Dialysis Therapy
Invited Editorial
Message From the President of the Japanese Society for Apheresis
vides the highest level of information of apheresis to the world. However, the medical community in Japan is currently facing many problems. The circumstance surrounding apheresis is no exception. Nevertheless, it is important for us to continue to seek new methods and indications for apheresis. There may be more diseases which we should treat by apheresis. We have to regain the initial point once again with a mind towards research for further development of the Society. I would like to promote advances in technology and research, and the dissemination of knowledge of the apheresis and its close relationship to clinical disease. Another important issue is to establish the evidence of efficacy of treatment with apheresis. Because of the rarity of the diseases which are indicative of apheresis therapy, it has been often difficult to carry out large randomized controlled trials. The JSFA, as a whole, should tackle the clinical trials to establish the evidence, and provide the information to the world. Now, the Japanese Board of Medical Specialties will require an educational program for the individual medical specialists or experts. It is also important for us to establish the educational system (boardcertified medical specialist system) so that we can effectively train medical specialists in all areas of Japan. It is impossible for only us to solve this problem. We must collaborate with other domestic and international academic societies. We should make any efforts to recruit young doctors and researchers into the field of apheresis. It is also our duty to certify other healthcare workers who support the teamwork in apheresis treatment, as specialists, and facilitate their training. Finally, the members of the JSFA have made remarkable achievements through presentations at international congresses such as the International Society for Apheresis (ISFA), and the publication of articles in academic journals, making an impact on apheresis medicine around the world. We should continue our efforts to develop research of apheresis
At the board meeting of the Japanese Society for Apheresis (JSFA) held on Sep 30, 2014, I was selected to serve as the new president of the society after the previous president Dr Tsuda. Given this opportunity, I would like to say a few words to the subscribers of Therapeutic Apheresis and Dialysis. As many readers already know, the JSFA has been expanding steadily and has flourished due to the great efforts of our predecessors. I would like to express sincere thanks to the previous presidents of the society and also to each president of the annual meetings. I intend to succeed to the founders’ spirits and to strive for further development of the JSFA, which is now at the turning point after the glories of the 1st generation. On my start as the president of the JSFA, I should like to address following issues. First of all, it is important to keep and enhance academic activity of the JSFA. The JSFA has made remarkable achievements, including development of new techniques and devices, and the application of new therapeutic techniques for patients who are suffering from a variety of diseases, most of which are resistant to ordinary treatments. Now, the JSFA pro199
200
Invited Editorial
with global relationships.We should also make efforts to disseminate the techniques and knowledge of apheresis to developing countries. To achieve these missions, we should require broad support not only from members of the JSFA, but also from the public as well. We should appreciate the continuing support and assistance of the ISFA,
Ther Apher Dial, Vol. 19, No. 3, 2015
Japanese Society of Dialysis Therapy, and subscribers of this journal. Hidenori Matsuo, MD, PhD President Japanese Society for Apheresis Email: [email protected]
© 2015 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society of Dialysis Therapy
Therapeutic Apheresis and Dialysis 2015; 19(3):199–200 doi: 10.1111/1744-9987.12321 © 2015 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society of Dialysis Therapy
Invited Editorial
Message From the President of the Japanese Society for Apheresis
vides the highest level of information of apheresis to the world. However, the medical community in Japan is currently facing many problems. The circumstance surrounding apheresis is no exception. Nevertheless, it is important for us to continue to seek new methods and indications for apheresis. There may be more diseases which we should treat by apheresis. We have to regain the initial point once again with a mind towards research for further development of the Society. I would like to promote advances in technology and research, and the dissemination of knowledge of the apheresis and its close relationship to clinical disease. Another important issue is to establish the evidence of efficacy of treatment with apheresis. Because of the rarity of the diseases which are indicative of apheresis therapy, it has been often difficult to carry out large randomized controlled trials. The JSFA, as a whole, should tackle the clinical trials to establish the evidence, and provide the information to the world. Now, the Japanese Board of Medical Specialties will require an educational program for the individual medical specialists or experts. It is also important for us to establish the educational system (boardcertified medical specialist system) so that we can effectively train medical specialists in all areas of Japan. It is impossible for only us to solve this problem. We must collaborate with other domestic and international academic societies. We should make any efforts to recruit young doctors and researchers into the field of apheresis. It is also our duty to certify other healthcare workers who support the teamwork in apheresis treatment, as specialists, and facilitate their training. Finally, the members of the JSFA have made remarkable achievements through presentations at international congresses such as the International Society for Apheresis (ISFA), and the publication of articles in academic journals, making an impact on apheresis medicine around the world. We should continue our efforts to develop research of apheresis
At the board meeting of the Japanese Society for Apheresis (JSFA) held on Sep 30, 2014, I was selected to serve as the new president of the society after the previous president Dr Tsuda. Given this opportunity, I would like to say a few words to the subscribers of Therapeutic Apheresis and Dialysis. As many readers already know, the JSFA has been expanding steadily and has flourished due to the great efforts of our predecessors. I would like to express sincere thanks to the previous presidents of the society and also to each president of the annual meetings. I intend to succeed to the founders’ spirits and to strive for further development of the JSFA, which is now at the turning point after the glories of the 1st generation. On my start as the president of the JSFA, I should like to address following issues. First of all, it is important to keep and enhance academic activity of the JSFA. The JSFA has made remarkable achievements, including development of new techniques and devices, and the application of new therapeutic techniques for patients who are suffering from a variety of diseases, most of which are resistant to ordinary treatments. Now, the JSFA pro199
200
Invited Editorial
with global relationships.We should also make efforts to disseminate the techniques and knowledge of apheresis to developing countries. To achieve these missions, we should require broad support not only from members of the JSFA, but also from the public as well. We should appreciate the continuing support and assistance of the ISFA,
Ther Apher Dial, Vol. 19, No. 3, 2015
Japanese Society of Dialysis Therapy, and subscribers of this journal. Hidenori Matsuo, MD, PhD President Japanese Society for Apheresis Email: [email protected]
© 2015 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society of Dialysis Therapy
